Yu X, Xie Y, Yu J, Zhang K, Guo Z, Wang D
World J Gastroenterol. 2025; 31(1):101198.
PMID: 39777247
PMC: 11684187.
DOI: 10.3748/wjg.v31.i1.101198.
Romeo M, Dallio M, Scognamiglio F, Ventriglia L, Cipullo M, Coppola A
Cancers (Basel). 2023; 15(21).
PMID: 37958352
PMC: 10647270.
DOI: 10.3390/cancers15215178.
Gupta M, Chandan K, Sarwat M
Curr Pharm Des. 2020; 26(4):415-428.
PMID: 31939724
PMC: 7403690.
DOI: 10.2174/1381612826666200115093835.
Wang X, Zhou X, Liu J, Liu Z, Zhang L, Gong Y
Int J Oncol. 2019; 55(4):860-878.
PMID: 31432149
PMC: 6741837.
DOI: 10.3892/ijo.2019.4858.
Chu Y, Jiang M, Du F, Chen D, Ye T, Xu B
FEBS Open Bio. 2018; 8(2):189-200.
PMID: 29435409
PMC: 5794460.
DOI: 10.1002/2211-5463.12363.
Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.
Wong C, Tsang F, Ng I
Nat Rev Gastroenterol Hepatol. 2018; 15(3):137-151.
PMID: 29317776
DOI: 10.1038/nrgastro.2017.169.
MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion.
Chen Y, Xu Q, Guo F, Guan W
Exp Ther Med. 2017; 13(2):681-687.
PMID: 28352351
PMC: 5348686.
DOI: 10.3892/etm.2016.3970.
Bioinformatic analysis of microRNA networks following the activation of the constitutive androstane receptor (CAR) in mouse liver.
Hao R, Su S, Wan Y, Shen F, Niu B, Coslo D
Biochim Biophys Acta. 2016; 1859(9):1228-1237.
PMID: 27080131
PMC: 4975621.
DOI: 10.1016/j.bbagrm.2016.04.002.
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375.
Yang T, Zhao P, Rong Z, Li B, Xue H, You J
Theranostics. 2016; 6(1):142-54.
PMID: 26722380
PMC: 4679361.
DOI: 10.7150/thno.13130.
Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
Huang M, Chen W, Qi F, Sun M, Xu T, Ma P
Mol Cancer. 2015; 14:165.
PMID: 26336870
PMC: 4558931.
DOI: 10.1186/s12943-015-0431-0.
MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility.
Tsang F, Au S, Wei L, Fan D, Lee J, Chak-Lui Wong C
Front Med. 2015; 9(3):331-43.
PMID: 26293610
DOI: 10.1007/s11684-015-0409-8.
Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
Tao J, Ji J, Li X, Ding N, Wu H, Liu Y
Oncotarget. 2015; 6(9):6977-88.
PMID: 25762642
PMC: 4466663.
DOI: 10.18632/oncotarget.3166.
Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.
Liu Y, Xia Y, Dai W, Han H, Dong Y, Cai J
BMC Cancer. 2014; 14:889.
PMID: 25429777
PMC: 4289300.
DOI: 10.1186/1471-2407-14-889.
miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN/AKT/PI3K pathway and HoxA10.
Xiao Z, Jiao C, Huang H, He L, Zhao J, Lu Z
Int J Clin Exp Pathol. 2014; 7(7):4039-44.
PMID: 25120782
PMC: 4129017.
MicroRNAs control hepatocarcinogenesis by regulating hepatocyte nuclear factor 4α-inflammatory signal feedback loops.
Wang H, Gao B
Hepatology. 2014; 60(5):1466-8.
PMID: 24996014
PMC: 4211960.
DOI: 10.1002/hep.27287.
Association between two common polymorphisms and risk of hepatocellular carcinoma: evidence from an updated meta-analysis.
Wang Z, Zhang L, Shi X, Xu H, Wang T, Bian J
Biomed Res Int. 2014; 2014:468605.
PMID: 24860819
PMC: 4016853.
DOI: 10.1155/2014/468605.
Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship.
Dibra D, Mishra L, Li S
Biochim Biophys Acta. 2014; 1846(1):152-60.
PMID: 24821201
PMC: 4140981.
DOI: 10.1016/j.bbcan.2014.05.001.
Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2.
Tsang F, Au V, Lu W, Shek F, Liu A, Luk J
Dig Dis Sci. 2014; 59(10):2477-87.
PMID: 24811246
DOI: 10.1007/s10620-014-3184-5.
Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation.
Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y
Gastroenterol Res Pract. 2013; 2013:719202.
PMID: 24194751
PMC: 3804138.
DOI: 10.1155/2013/719202.
Evidence for and against epithelial-to-mesenchymal transition in the liver.
Xie G, Diehl A
Am J Physiol Gastrointest Liver Physiol. 2013; 305(12):G881-90.
PMID: 24157970
PMC: 3882441.
DOI: 10.1152/ajpgi.00289.2013.